Annovis Bio, Inc.
Annovis Bio, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 13, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.
Cash runway is approximately 6.2 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 5 concluded trials, 80% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 13, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| December 15, 2027 | A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD | Trial Milestone | Phase 3 |
| September 15, 2029 | A Study of Buntanetap in Participants With PD | Trial Milestone | Phase 2/Phase 3 |
| February 21, 2030 | An Open-label Long-term Safety Study of Buntanetap in Participants With AD | Trial Milestone | Phase 2/Phase 3 |
Track ANVS alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open ANVS in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.